MONTREAL, Jan. 08, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive agreement with OCuSOFT Inc. for distribution rights in the United States for its patented I-PEN® Osmolarity System. On December 22, 2017 the FDA issued an Acceptance Review Notification for the I-PEN® Osmolarity System 510k submission. This distribution partnership will officially commence upon final FDA approval of the 510k, which is anticipated in the first quarter of 2018.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9e4c7695-0adf-443f-b28f-52d13059969d
The I-PEN® Osmolarity System is the world’s first, handheld platform that offers eye care professionals a quick and reliable tool for screening dry eye patients.
Daniel Hofmann, President of I-MED Pharma stated, “We are thrilled to partner with OCuSOFT, a company recognized for addressing clinical needs with innovative solutions. The I-PEN® Osmolarity System is an invaluable asset for measuring tear osmolarity, a key step in identifying the presence and severity of dry eye disease. We believe that this partnership will offer the first economical solution for eye care professionals looking for an efficient and reliable diagnostic tool in this area.”
Cynthia Barratt, President and CEO of OCuSOFT states, “OCuSOFT is extremely excited about the I-Pen® Osmolarity System and we know clinicians will be too. Continuing research demonstrates the importance of testing tear film osmolarity and now with I-Pen®, there is an affordable means to do so. I-Pen® is a hand-held device that practitioners can utilize in-office. It is efficient and highly reliable, enabling practitioners to diagnose and treat Dry Eye with confidence.” OCuSOFT Inc. will be making a future announcement as to availability.
I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established almost thirty years ago, I-MED Pharma creates and distributes innovative medical, surgical and veterinary eye care products worldwide. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degeneration, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops and ocular occlusion devices.
About OCuSOFT Inc.
OCuSOFT Inc. is a privately held Richmond, TX USA-based research, development and supply company specializing in eye and skin care that started with a vision to address the needs of those suffering from ocular surface disease with innovative solutions. Since 1986, OCuSOFT’s commitment to health care professionals and their patients has been unparalleled. Today, it is recognized by eye care professionals for its standing as the preferred distributor of ophthalmic products and supplies.
For more information, please email media@imedpharma.com or visit www.imedpharma.com.